**Core tip:** The long-term effects of clopidogrel in patients with and without diabetes mellitus (DM) have not been systematically reviewed. The present meta-analysis firstly investigated the modifying effect of DM on the efficacy of long-term clopidogrel treatment in patients with ischemic cardiovascular disease. Although the analysis showed that the hazard ratio reduction in patients with DM was less than that in those without, this difference was not significant. The efficacy of dual antiplatelet therapy with clopidogrel and aspirin appeared to be slightly lower in patients with DM, emphasizing the need for individualized antiplatelet treatment for patients with DM after myocardial infarction or ischemic stroke.

INTRODUCTION
============

Ischemic cardiovascular disease remains the leading cause of mortality globally\[[@B1],[@B2]\]. Early initiation of dual antiplatelet therapy with a P2Y~12~ receptor antagonist plus aspirin is recommended for patients with ischemic cardiovascular disease in the current guidelines\[[@B3],[@B4]\]. Clopidogrel remains the most widely prescribed P2Y~12~ receptor antagonist and is recommended by the latest guidelines for the management of ischemic stroke and acute coronary syndromes (ACS)\[[@B5],[@B6]\]. Studies have shown that patients with diabetes mellitus (DM) exhibit a poorer response to clopidogrel than patients without DM\[[@B7],[@B8]\], leading to a significant difference in the incidence of recurrence of cardiovascular events and mortality associated with DM\[[@B9]\].

Previous research has shown that hyperglycemia increases platelet reactivity, and the underlying mechanisms include higher platelet receptor expression, intracellular downstream signaling abnormalities, and P2Y~12~ mutation and expression level\[[@B7],[@B10]\]. The findings of the OPTIMUS trial, which compared the efficacy of a 150-mg maintenance dose of clopidogrel with 75 mg in 40 patients with both DM and coronary artery disease, showed that the higher maintenance dose of clopidogrel is associated with greater antiplatelet effects\[[@B11]\]. Hence, it is reasonable to hypothesize that clopidogrel treatment of ischemic vascular disease would be associated with a less substantial reduction in the risk of cardiovascular events in patients with DM than in those without.

Subgroup analyses of data from several randomized controlled trials (RCTs) comparing the efficacy of a combination of clopidogrel and aspirin with aspirin alone have shown that DM reduces the effect of clopidogrel on the incidence of recurrence of cardiovascular events and all-cause mortality, although the interactions were not significant\[[@B12]-[@B14]\]. A large-scale cohort study also showed that DM was associated with a lower efficacy of clopidogrel for a reduction in 1-year cardiovascular mortality in patients with myocardial infarction\[[@B9]\]. However, the long-term effects of clopidogrel in patients with and without DM have not been systematically reviewed. Therefore, we hypothesized that the presence of DM modifies the long-term efficacy of clopidogrel for a reduction in cardiovascular risk, and we performed a systematic review and meta-analysis to test this hypothesis.

MATERIALS AND METHODS
=====================

This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement\[[@B15]\].

Data sources
------------

The literature search was conducted on 27 June 2019 using the Cochrane Library database for trials, EMBASE, and PubMed. The search strategy was: (1) PubMed (from 1980) 2019/06/27, (clopidogrel\[Title/Abstract\]) AND aspirin\[Title/Abstract\], article types: Clinical Trial; (2) EMBASE (from 1980) 2019/06/27, \#2 \#1 AND \'randomized controlled trial\'/de, \#1 \'clopidogrel\':ab,ti AND \'aspirin\':ab,ti; and (3) Cochrane Central Register of Controlled Trials (CENTRAL, from 1980) 2019/06/27, keywords: ("clopidogrel" AND "aspirin"); search limits: Trials.

Study selection
---------------

The inclusion criteria for RCTs were double-blind design, clopidogrel and aspirin *vs* aspirin for the treatment of ischemic cardiovascular disease, age ≥ 18 years, subgroup analysis according to the presence of diabetes (if not reported, the corresponding author was contacted to obtain the data)\[[@B16]\], and a duration of treatment ≥ 3 mo\[[@B17]\]. We also included the CHARISMA trial, because the percentage of patients with documented vascular disease in the trial was high (78%)\[[@B14]\].

Outcome
-------

The outcomes assessed in the meta-analysis were fatal and non-fatal cardiovascular events. Table [1](#T1){ref-type="table"} summarizes the definitions of the primary outcomes of the included RCTs.

###### 

Definitions of the primary efficacy outcome in each of the included trials

  **Trial**      **Definition of primary efficacy outcome**
  -------------- --------------------------------------------------------------------------------------------------
  CHANCE 2013    Stroke recurrence (ischemic or hemorrhagic).
  CHARISM 2006   The composite of myocardial infarction, stroke, or death from cardiovascular causes.
  CREDO 2002     The composite of death, myocardial infarction, and stroke.
  CURE 2001      The composite of myocardial infarction, stroke, or death from cardiovascular causes.
  POINT 2018     The composite of ischemic stroke, myocardial infarction, or death from ischemic vascular causes.
  SPS3 2012      Stroke recurrence (ischemic or hemorrhagic).

Quality assessment and data extraction
--------------------------------------

Two researchers (Liang LR and Ma Q) used a specially designed questionnaire to extract data independently. Consensus was reached by discussion. The Cochrane Collaboration's risk-of-bias table was used to assess the quality of the included RCTs independently by two authors (Feng L and Xie WX)\[[@B18]\]. Figure [1](#F1){ref-type="fig"} shows the risk of bias in the RCTs.

![Risk-of-bias of included trials. A: Judgements about each source of bias in each study; B: Review authors' judgements regarding the risk of each source of bias. The data are presented as percentages across all the included studies and are classified as Low, Unclear, or High. We followed the recommended approach for assessing the risk of bias in studies included in the Cochrane Handbook for Systematic Reviews of Interventions, version 5.3.0. This addresses seven specific domains: Random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Each domain includes one or more specific entries in a "Risk of bias" table. The tool involves assigning a judgement relating to the risk of bias for that entry. This is achieved by answering a pre-specified question about the adequacy of the study in relation to the entry, such that a judgement of "Yes" indicates a low risk of bias, "No" indicates a high risk of bias, and 'Unclear' indicates an unclear or unknown risk of bias.](WJD-11-137-g001){#F1}

Statistical analysis
--------------------

Review Manager 5.3 (Nordic Cochrane Center, Copenhagen, Denmark) was used to conduct the meta-analysis within random-effect models to estimate the pooled hazard ratio (HR) and its 95% confidence interval (CI). Sensitivity analysis was also performed using fixed-effect models. To evaluate the modifying effect of DM on the efficacy of clopidogrel, we used the *Z*-test to compare the difference between the two pooled HRs from the subgroup analyses, using the method proposed by Altman and Bland\[[@B19]\]. We used the *I*^2^ statistic to estimate the heterogeneity of the included RCTs, and the Egger test and funnel plots to estimate the level of publication bias in STATA (version 11; Stata Corp, College Station, TX). All analyses were two-sided, and an alpha value of 0.05 was used as the threshold for statistical significance.

RESULTS
=======

Study characteristics
---------------------

Figure [2](#F2){ref-type="fig"} shows the study selection process, which was conducted according to the PRISMA statement. Two thousand and sixty-four publications were identified in the initial search, from which 598 duplicates were excluded, and a further 1432 articles were removed after reviewing their title and abstract. The full text of the remaining 34 articles was then reviewed independently by two researchers, and 28 of these were excluded because of a treatment duration \< 3 mo, a lack of comparison between clopidogrel plus aspirin and aspirin alone, a lack of subgroup analysis according to the presence of DM, a long-term *vs* short-term analysis, a high-dose *vs* low-dose analysis, ACS or ischemic stroke patients were not studied, or duplication (Table [2](#T2){ref-type="table"}). Therefore, six RCTs, comprising 43352 participants (13491 with and 29861 without DM), were eligible for the present analysis\[[@B12]-[@B14],[@B16],[@B20],[@B21]\]. Table [3](#T3){ref-type="table"} presents the characteristics of the included RCTs, of which three had recruited patients who had experienced an ischemic stroke or transient ischemic attack, two had recruited ACS patients, and one had recruited patients with cardiovascular disease or multiple risk factors. Table [4](#T4){ref-type="table"} summarizes the antiplatelet treatments and daily doses used in these trials.

###### 

Characteristics of the excluded trials

  **Title**                                                                                                                                                                                               **Reason for exclusion**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  A randomised, blinded, trial of clopidogrel *vs* aspirin in patients at risk of ischaemic events (CAPRIE)                                                                                               Not clopidogrel + aspirin *vs* aspirin
  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation                                                                                         Treatment duration \< 3 mo; Not report subgroup results
  Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: Randomised placebo-controlled trial                                                                              Treatment duration \< 3 mo; Not report subgroup results
  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial   Not clopidogrel + aspirin *vs* aspirin
  Aspirin and extended-release dipyridamole *vs* clopidogrel for recurrent stroke                                                                                                                         Not clopidogrel + aspirin *vs* aspirin
  Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery                                                                                              Treatment duration \< 3 mo
  Aspirin plus clopidogrel *vs* aspirin alone after coronary artery bypass grafting: The clopidogrel after surgery for coronary artery disease (CASCADE) Trial                                            Not report subgroup results
  Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin *vs* aspirin alone                                                                                       Duplicate trials
  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: One year outcomes                                                                                           Duplicate trials
  Dose comparisons of clopidogrel and aspirin in acute coronary syndromes                                                                                                                                 High dose *vs* low dose
  Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents                                                                                                                         Long-term *vs* short-term
  Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome                                                                           Not clopidogrel + aspirin *vs* aspirin
  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics                                             Treatment duration \< 3 mo
  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study                                        Duplicate trials
  Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial                                                                      Not report subgroup results
  Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response -- The TAILOR randomized trial                                                                                                Not clopidogrel + aspirin *vs* aspirin
  Prasugrel *vs* clopidogrel for acute coronary syndromes without revascularization                                                                                                                       Not clopidogrel + aspirin *vs* aspirin
  Prasugrel *vs* clopidogrel in patients with acute coronary syndromes                                                                                                                                    Not clopidogrel + aspirin *vs* aspirin
  PROCLAIM: Pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.                                                     Treatment duration \< 3 mo
  Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination *vs* aspirin alone after lower limb angioplasty                                                                Treatment duration \< 3 mo
  Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention                                                  Not clopidogrel + aspirin *vs* aspirin
  Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial                                                     Not report subgroup results
  Ticagrelor *vs* aspirin in acute stroke or transient ischemic attack                                                                                                                                    Not clopidogrel + aspirin *vs* aspirin
  Ticagrelor *vs* clopidogrel in patients with acute coronary syndromes                                                                                                                                   Not clopidogrel + aspirin *vs* aspirin
  Ticagrelor *vs* clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction                                                                                              Not clopidogrel + aspirin *vs* aspirin
  Ticagrelor *vs*. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome                                                                                                    Not clopidogrel + aspirin *vs* aspirin
  Twelve or 30 mo of dual antiplatelet therapy after drug-eluting stents                                                                                                                                  Long-term *vs* short-term
  Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation                                                                                                                             Not ACS or ischemic stroke patients

![Study selection flow chart.](WJD-11-137-g002){#F2}

###### 

Baseline characteristics of participants in the included trials

  **Trial**       **Country**                **Centers**   **Patients**                             **Sample size**   **Male %**   **Mean age Y**   **Diabetes%**   **Treatment duration M**   **Lost to follow-up %**   **Blinding**   **ITT analysis**
  --------------- -------------------------- ------------- ---------------------------------------- ----------------- ------------ ---------------- --------------- -------------------------- ------------------------- -------------- ------------------
  CHANCE 2013     China                      114           Minor ischemic stroke or high-risk TIA   5170              66           63               21              3                          0.7                       Double-blind   Yes
  CHARI-SM 2006   Worldwide                  768           CVD or multiple risk factors             15603             70           64               42              28                         0.5                       Double-blind   Yes
  CREDO 2002      United States and Canada   99            Those would undergo elective PCI         2116              71           62               26              12                         1.1                       Double-blind   Yes
  CURE 2001       Worldwide                  482           ACS without ST-segment elevation         12562             62           64               23              12                         0.1                       Double-blind   Yes
  POINT 2018      Worldwide                  269           Acute ischemic stroke or high-risk TIA   4881              55           65               27              3                          4.1                       Double-blind   Yes
  SPS3 2012       Worldwide                  82            Recent symptomatic lacunar infarcts      3020              63           63               36              41                         2.0                       Double-blind   Yes

ITT: Intention-to-treat; TIA: Transient ischemic attack; CVD: Cardiovascular disease; PCI: Percutaneous coronary intervention; ACS: Acute coronary syndromes.

###### 

Antiplatelet treatments and the daily doses used in the included trials

  **Trial**      **Drug (daily doses, mg)**                                                                           
  -------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  CHANCE 2013    Clopidogrel (day 1: 300; day 2-90: 75) + Aspirin (day 1: 75-300; day 2-21: 75; day 22-90: placebo)   Aspirin (day 1: 75-300; day 2-90: 75)
  CHARISM 2006   Clopidogrel (75) + Aspirin (75-162)                                                                  Aspirin (75-162)
  CREDO 2002     Clopidogrel (day 1: 300; day 2 to 12 mo: 75) + Aspirin (day 1: 325; day 2 to 12 mo: 81-325)          Clopidogrel (day 2-28: 75) + Aspirin (day 1: 325; day 2 to 12 mo: 81-325)
  CURE 2001      Clopidogrel (day 1: 300, and then 75) + Aspirin (75-325)                                             Aspirin (75-325)
  POINT 2018     Clopidogrel (day 1: 600, and then 75) + Aspirin (50-325)                                             Aspirin (50-325)
  SPS3 2012      Clopidogrel (75) + Aspirin (325)                                                                     Aspirin (325)

Effect of clopidogrel, according to diabetes status
---------------------------------------------------

As shown in Figure [3](#F3){ref-type="fig"}, compared with aspirin alone, the addition of clopidogrel to aspirin significantly reduced the risk of any cardiovascular event in patients without DM (HR = 0.78, 95%CI: 0.71--0.86, *P* \< 0.001; *I*^2^ = 23%, *P* = 0.26) and also in patients with DM, although the benefit was less (HR = 0.89, 95%CI: 0.81-0.99, *P* = 0.030; *I*^2^ = 0%, *P* = 0.74). The presence of DM was associated with an 11% higher HR, although the difference in the efficacy of clopidogrel in patients with and without DM did not reach significance (*P* for interaction = 0.062).

![Meta-analyses using random-effect models conducted on the pooled data describing the effect of clopidogrel treatment on the incidence of any cardiovascular event. A: In patients without diabetes mellitus; B: In patients with diabetes mellitus. DAPT: Dual antiplatelet therapy.](WJD-11-137-g003){#F3}

Publication bias
----------------

Both funnel plots (Figure [4](#F4){ref-type="fig"}) and Egger tests (*P* = 0.592 for patients without DM, and *P* = 0.296 for patients with DM) showed no evidence of publication bias.

![Funnel plot for the included studies, used to evaluate the effect of clopidogrel on the incidence of any cardiovascular event. A: In patients without diabetes mellitus; B: In patients with diabetes mellitus.](WJD-11-137-g004){#F4}

Sensitivity analysis
--------------------

The pooled results of a meta-analysis using fixed-effect models was consistent with the principal findings of random-effect models (Figure [5](#F5){ref-type="fig"}). Clopidogrel treatment was associated with relative risk reductions of 11% (HR = 0.89, 95%CI: 0.81--0.99, *P* = 0.030) and 21% (HR = 0.79, 95%CI: 0.73-0.85, *P* \< 0.001) for any cardiovascular event in patients with and without DM, respectively. However, the modifying effect of DM on the incidence of cardiovascular events was not significant (*P* for interaction = 0.064).

![Meta-analyses using fixed-effect models conducted on the pooled data describing the effect of clopidogrel treatment on the incidence of any cardiovascular event. A: In patients without diabetes mellitus; B: In patients with diabetes mellitus. DAPT: Dual antiplatelet therapy.](WJD-11-137-g005){#F5}

DISCUSSION
==========

Our systematic review and meta-analysis found that the addition of clopidogrel to aspirin significantly reduced the risk of any cardiovascular event in patients with or without DM. In addition, the results show that the presence of DM is associated with an increase of 11% in the HR, although this difference was not significant. To our knowledge, this is the first meta-analysis to evaluate the efficacy of long-term clopidogrel treatment in patients with ischemic cardiovascular disease, according to the presence or absence of DM.

The latest evidence provided by head-to-head RCTs has led to the current guidelines for the management of ACS stating that clopidogrel is inferior to ticagrelor and prasugrel as a P2Y~12~ inhibitor for patients with ST-segment elevation myocardial infarction or non-STE ACS\[[@B3],[@B4]\]. Recently, subgroup analyses of these RCTs have shown that the effects of ticagrelor and prasugrel are not modified by the presence of DM\[[@B22],[@B23]\]. Evidence from previous trials and the present meta-analysis indicate that it is reasonable to use ticagrelor or prasugrel in preference to clopidogrel for the treatment of ACS patients, and especially those with DM. However, it should be noted that both ticagrelor and prasugrel are associated with higher risks of bleeding than clopidogrel; therefore, clopidogrel can still be used if ticagrelor and prasugrel are not available or are contraindicated\[[@B3],[@B4]\]. Furthermore, data regarding the clinical efficacy and safety of ticagrelor or prasugrel for the treatment of ischemic stroke are limited. The SOCRATES trial, which compared the efficacy and safety of ticagrelor and aspirin in 13199 patients who had experienced a mild ischemic stroke or high-risk transient ischemic attack, found that ticagrelor was no more effective than aspirin at lowering cardiovascular risk over 90 days\[[@B24]\]. Therefore, clopidogrel remains the first choice of P2Y~12~ inhibitor for the treatment of ischemic stroke\[[@B6]\]. In the present study, a weaker effect of clopidogrel was identified in patients with DM, which implies that a new antiplatelet agent is needed for ischemic stroke patients with DM.

A prospective cohort study of 58851 patients who had experienced a myocardial infarction confirmed this hypothesis\[[@B9]\]. Andersson and colleagues reported that clopidogrel treatment was associated with lesser reductions in 1-year all-cause mortality and cardiovascular mortality in patients with DM, compared to those without\[[@B9]\]. The results of the large-scale cohort study were consistent with the present findings, and we consider that one of the most important reasons why the present meta-analysis did not demonstrate a modifying effect of DM was the relatively small number of RCTs included. Therefore, a second meta-analysis should be performed when data from additional RCTs become available.

Several potential mechanisms that might explain the variability in the response to clopidogrel have been suggested. Firstly, a pharmacokinetic study showed that variability in intestinal absorption is the principal cause\[[@B25]\]. Second, polymorphisms in hepatic cytochrome (CYP) P450 3A, including in CYP3A4 and CYP3A5, may also be important: An inverse correlation has been shown between the percentage platelet aggregation and CYP3A4 activity in clopidogrel users\[[@B26]\]. In particular, of the multiple polymorphisms of CYP3A4, the IVS10 + 12G\>A variant has been shown to regulate clopidogrel responsiveness\[[@B27]\]. Furthermore, a CYP3A5 polymorphism has been shown to be associated with atherothrombosis after clopidogrel treatment\[[@B28]\], although there is new evidence that challenges the existence of the association between CYP3A5 genotype and clopidogrel response\[[@B29]\]. Third, genetic platelet receptor polymorphisms have been implicated. Single-nucleotide polymorphisms of platelet receptors, such as GP IIIa L33P (= PlA1/2) and GP Ia 807 C/T have been suggested to be risk factors for thrombosis\[[@B30]\]. Fourth, the use of concurrent medication, such as calcium channel blockers, has recently been demonstrated to be a predictor of atherothrombotic events after clopidogrel treatment\[[@B29]\]. These mechanisms might also explain the effect of DM on the clopidogrel response.

Our study had several strengths: The inclusion of high-quality RCTs, large samples, no significant heterogeneity among the studies, and no evidence of publication bias. However, the study also had some limitations. First, the primary outcomes of the included RCTs were not entirely consistent, and secondary outcome data cannot be collected, because publications describing RCTs only show subgroup data for the primary outcomes. The present study only pooled the results of the primary outcomes of the included trials, which may have caused bias. Second, we estimated the pooled HRs on the basis of trial-level data, whereas pooled HRs derived from individual-level data would be more accurate. Third, although we conducted a thorough literature search to identify relevant RCTs, it is possible that some appropriate RCTs were not included in this study, implying the possibility of selection bias.

In conclusion, the present study found that the addition of clopidogrel to aspirin significantly reduced cardiovascular risk in patients with and without DM who had experienced ischemic cardiovascular disease. The beneficial effect of a combination of clopidogrel and aspirin for patients with DM appeared to be lower than that for patients without DM, although this difference did not reach significance.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Clopidogrel remains the most widely prescribed P2Y~12~ receptor antagonist and is recommended by the latest guidelines for the management of ischemic stroke and acute coronary syndromes. Studies have shown that patients with diabetes mellitus (DM) exhibit a poorer response to clopidogrel than patients without DM, leading to a significant difference in the incidence of recurrence of cardiovascular events and mortality associated with DM. However, the long-term effects of clopidogrel in patients with and without DM have not been systematically reviewed.

Research motivation
-------------------

We hypothesized that the presence of DM modifies the long-term efficacy of clopidogrel for a reduction in cardiovascular risk. To our knowledge, this is the first meta-analysis to evaluate the efficacy of long-term clopidogrel treatment in patients with ischemic cardiovascular disease, according to the presence or absence of DM.

Research objectives
-------------------

This study aimed to systematically evaluate the efficacy of clopidogrel for the treatment of acute coronary syndromes or ischemic stroke in patients with or without DM.

Research methods
----------------

A systematic review and meta-analysis of randomized controlled trials.

Research results
----------------

Six randomized controlled trials, comprising 43,352 participants (13,491 with and 29,861 without DM) who had received antiplatelet therapy for ≥ 3 mo, were included in the meta-analysis. Compared with aspirin alone, a combination of clopidogrel and aspirin significantly reduced the risk of any cardiovascular event in patients without DM (HR = 0.78, 95%CI: 0.71--0.86, *P* \< 0.001; *I*^2^ = 23%, *P* = 0.26). Clopidogrel plus aspirin also significantly reduced cardiovascular risk in patients with DM, although the effect was smaller (HR = 0.89, 95%CI: 0.81--0.99, *P* = 0.030; *I*^2^ = 0%, *P* = 0.74). Nevertheless, there was no significant difference in the efficacy of clopidogrel at reducing the risk of cardiovascular events in patients with DM *vs* those without (*P* for interaction = 0.062).

Research conclusions
--------------------

The present study found that the addition of clopidogrel to aspirin significantly reduced cardiovascular risk in patients with and without DM who had experienced ischemic cardiovascular disease. The beneficial effect of the addition of clopidogrel to aspirin for patients with DM was lower than that in patients without DM, although the modifying effect of DM did not reach significance. In the present study, a weaker effect of clopidogrel was identified in patients with DM, which implies that a new antiplatelet agent is needed for ischemic stroke patients with DM. We hypothesized that the presence of DM modifies the long-term efficacy of clopidogrel for a reduction in cardiovascular risk. Cardiologist and neurologist should pay attention to the presence of DM when provide clopidogrel for patients with ischemic cardiovascular disease.

Research perspectives
---------------------

A systematic review and meta-analysis of randomized controlled trials to summarize the evidence on this topic is important. A new antiplatelet agent is needed for ischemic stroke patients with DM.
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